PT  - JOURNAL ARTICLE
AU  - Joseph C. Masdeu
AU  - Belen Pascual
AU  - Masahiro Fujita
TI  - Imaging Neuroinflammation in Neurodegenerative Disorders
AID  - 10.2967/jnumed.121.263200
DP  - 2022 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 45S--52S
VI  - 63
IP  - Supplement 1
4099  - http://jnm.snmjournals.org/content/63/Supplement_1/45S.short
4100  - http://jnm.snmjournals.org/content/63/Supplement_1/45S.full
SO  - J Nucl Med2022 Jun 01; 63
AB  - Neuroinflammation plays a major role in the etiopathology of neurodegenerative diseases, including Alzheimer and Parkinson diseases, frontotemporal lobar degeneration, and amyotrophic lateral sclerosis. In vivo monitoring of neuroinflammation using PET is critical to understand this process, and data are accumulating in this regard, thus a review is useful. From PubMed, we retrieved publications using any of the available PET tracers to image neuroinflammation in humans as well as selected articles dealing with experimental animal models or the chemistry of currently used or potential radiotracers. We reviewed 280 articles. The most common PET neuroinflammation target, translocator protein (TSPO), has limitations, lacking cellular specificity and the ability to separate neuroprotective from neurotoxic inflammation. However, TSPO PET is useful to define the amount and location of inflammation in the brain of people with neurodegenerative disorders. We describe the characteristics of TSPO and other potential PET neuroinflammation targets and PET tracers available or in development. Despite target and tracer limitations, in recent years there has been a sharp increase in the number of reports of neuroinflammation PET in humans. The most studied has been Alzheimer disease, in which neuroinflammation seems initially neuroprotective and neurotoxic later in the progression of the disease. We describe the findings in all the major neurodegenerative disorders. Neuroinflammation PET is an indispensable tool to understand the process of neurodegeneration, particularly in humans, as well as to validate target engagement in therapeutic clinical trials.